ABBV-119
- Generic Name
- ABBV-119
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
Phase 2
Terminated
- Conditions
- Cystic Fibrosis (CF)
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT04853368
- Locations
- 🇺🇸
University of Southern California /ID# 249147, Los Angeles, California, United States
🇺🇸UH Cleveland Medical Center /ID# 245433, Cleveland, Ohio, United States
🇺🇸Boston Children's Hospital /ID# 248646, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath